Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
22 févr. 2022 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems to Present at Upcoming Virtual Investor Conferences
10 févr. 2022 16h30 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
07 févr. 2022 16h01 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research
03 févr. 2022 16h30 HE
|
Delcath Systems, Inc.
Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of...
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
25 janv. 2022 16h01 HE
|
Delcath Systems, Inc.
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
07 janv. 2022 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
02 déc. 2021 08h00 HE
|
Delcath Systems, Inc.
On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall...
Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting
30 nov. 2021 08h30 HE
|
Delcath Systems, Inc.
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems Announces Third Quarter 2021 Results
09 nov. 2021 07h30 HE
|
Delcath Systems, Inc.
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021
08 nov. 2021 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...